Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   

National Institute on Drug Abuse

Director's Report to the National Advisory Council on Drug Abuse

September, 2000


Staff Highlights


Honors and Awards

Ms. Carol Sneeringer, IRP, received the NIH Director's Award in June 2000: "In recognition of outstanding contributions in support of the mission of the Intramural Research Program of the National Institute on Drug Abuse".

Dr. Jaylan S. Turkkan, DNBR, received two NIH Director's Awards in June 2000. These were: from NIDA: "For superb leadership, resourcefulness and innovative approaches to the investigations of new ways to combat tobacco use and nicotine addiction;" and from NCI: Group award, The Transdisciplinary Tobacco Use Research Centers Implementation Group: "For creating and implementing the TTURC Program, a model for collaborative research and public/private partnerships".

The Buprenorphine Development Team received the HHS Secretary's Distinguished Award for their outstanding performance in development of Buprenorphine products as treatment agents for opiate dependence.

Dr. Elizabeth Rahdert, DTR&D, received the Division of Family Psychology Distinguished Service to Family Psychology Award, August 4, 2000, at the 108th Annual Convention of the American Psychological Association held in Washington DC.

Dr. Jack Blaine and Dr. Lisa Onken, DTR&D each received a Distinguished Friend to Behavioral Therapy Award from the American Academy of Behavioral Therapy (AABT) as special recognition for their work in spearheading and fostering the growth of efficacious behavioral treatments for drug abuse, as well as concomitant disorders. The AABT will present the awards to Drs. Blaine and Onken at their annual meeting on November 17, 2000 in New Orleans, LA.

CDR Peter J. Delany, D.S.W., received the year 2000 Public Health Service Social Worker of the Year Award on June 10, 2000. He was recognized by RADM Kenneth Moritsugu, Deputy Surgeon General for his "Outstanding leadership in promotion of critical public health research and commitment to public health social work services." Dr. Delany is currently the Acting Deputy Director of the Division of Epidemiology, Services and Prevention Research.

William J. Bukoski, Ph.D., DESPR, received a special recognition award from The Metropolitan Washington Council of Governments for ten years of outstanding service in drug abuse prevention science that directly benefited prevention practitioners in the Washington, D.C. metropolitan area.

Dr. Jerry Flanzer, DESPR, was appointed for a two year term as the Chair of the National Steering Committee of the Alcohol, Tobacco and Drug Section of the National Association for Social Workers. Dr. Flanzer also earned the status of Life Fellow of the American Orthopsychiatric Association (2000).

Dr. Peter Hartsock, CAMCODA, was awarded a special commendation from the Russian Association Against HIV/AIDS at the 8th International Conference on AIDS, Cancer, and Related Problems, St. Petersburg, Russia, May 2000. The commendation was presented to Dr. Hartsock "to acknowledge his invaluable contribution towards building cooperative relations between the Russian Federation and the United States of America in HIV prevention among Injecting Drug Users" and reflects 20 years of cooperation-building efforts.

Dr. Jonathan L. Katz, IRP, was invited to serve as a member of the Executive Committee of the Division for Behavioral Pharmacology and as a Program Committee Member, American Society for Pharmacology and Experimental Therapeutics.

Dr. Jonathan L. Katz, IRP, was invited to serve as chair of the Liaison Committee for Drug Testing and Evaluation, of the College on Problems of Drug Dependence.

Dr. Jonathan L. Katz, IRP, was elected to a two-year term as President of the Behavioral Pharmacology Society.


Staff Changes

Dr. Lucinda Miner has been selected for the position of Chief, Science Policy Branch, OSPC. She received her Ph.D. from the University of Colorado in 1986. She started at NIDA in 1992 to work in the Intramural Research Program in Baltimore. While at the IRP, NIDA, she helped to establish the Molecular Genetics Section and worked closely with Dr. George Uhl to develop their transgenic mouse facilities. She joined the Science Policy Branch in 1996 to serve as the Deputy Research Training Coordinator. In that capacity, she has helped to increase the visibility of NIDA's research training programs and has assisted numerous young investigators in their efforts to launch their research careers. In 1999, she was promoted to Deputy Chief of the Science Policy Branch and has been serving as the Acting Director for the last several months.

Garveyette Brown joined the Public Information Branch of OSPC as a Program Assistant in June 2000. Formerly, Ms. Brown taught second and third graders in the D.C. Public Schools as well as Baltimore City Public Schools. Prior to her teaching career, Ms. Brown was a Communications Industry Analyst at the Federal Communications Commission, where she was instrumental in processing and granting many station licenses for AM/TV stations as well as mobile phones. Ms. Brown has also been a secretary for a congressman and a senator. She has a B.S. degree in Elementary Education from Bowie State University.

Dr. Naresh Chand joined the Medications Discovery & Toxicology Branch of DTR&D as a Health Scientist Administrator on August 28, 2000. Prior to joining NIDA, Dr. Chand spent 20 years in the pharmaceutical industry. He served as Director of the Department of Pharmacology at Wallace Laboratories and as Associate Director of Drug Safety Evaluation at Otsuka America Pharmaceuticals. Dr. Chand will oversee a portion of the Division's growing workload in the area of preclinical safety assessment and will assume full responsibility for shaping and directing a preclinical program focused on cardiovascular drug interaction studies.

Dr. Mary Ann Chutuape came to the CTN office of DTR&D as a Special Expert in June 2000. Prior to joining NIDA, Dr. Chutuape was Project Director for a NIDA-funded substance abuse treatment research clinic at Johns Hopkins University School of Medicine, where she was appointed as an Assistant Professor in the Department of Psychiatry. Her research focused on behavioral and pharmacotherapy clinical trials for opioid dependence. Dr. Chutuape received her Ph.D. in Behavioral Sciences from the University of Chicago.

Katia Delrahim joined the CTN Office of DTR&D in July 2000 as a summer intern. She is a fourth year Biological Anthropology student at the University of California, San Diego. She is planning a career in the medical profession, and will be with the CTN until the end of August.

Donna Inman joined NIDA's Division of Treatment Research and Development as a Clinical Trials Specialist on August 27, 2000. Before coming to NIDA, Ms. Inman was a Project Specialist with the FDA's Center for Drug Evaluation and Research (CDER).

Anne Jarrett joined NIDA in July 2000 as the Secretary to the Associate Director. Previously, she was the Executive Assistant to the President of American Councils for International Education, a non-profit educational organization that deals with student and teacher exchanges between the U.S. and the former Soviet Union. Prior to this she was an assistant to the Public Affairs Manager at Resources for the Future, an environmental think tank with a focus on economics. She developed and maintained a database of congressional staff, in addition to writing occasional press releases.

Catherine Law joined NIDA in July 2000 as a science writer and editor in OSPC's Science Policy Branch. She has a Bachelor of Science degree in Chemistry from Kent State University (1993) and a Master of Technical and Scientific Communication degree from Miami University (1998). She began working at NIH in 1996 as a Graduate Health Communications Intern in the National Cancer Institute's Mass Media Branch. In 1997, she moved to NCI's Office of Science Planning and Assessment (OSPA) as a Technology Transfer Fellow and was hired as a permanent staff member in 1999. She was a member of OSPA's Science Policy and Planning Team, which prepares NCI's annual Bypass Budget and handles a variety of other science policy and planning projects.

Dr. E. Douglas Kramer recently joined the Clinical Trials Network (CTN) office of DTR&D. He came from FDA's Center for Drug Evaluation and Research where he was extensively involved in the review of pharmacotherapies for addictive disorders. Dr. Kramer received his medical degree and residency training in pathology at Columbia University in New York.

Dr. Cecelia Lee McNamara recently joined the Clinical Trials Network Office of DTR&D as a Health Scientist Administrator. Cecelia received her doctorate in clinical psychology from the University of New Mexico where she received training in behavioral treatments for substance abuse. As a post-doctoral fellow at the University of Alabama at Birmingham with Jesse Milby, Ph.D. and Joe Schumacher, Ph.D, she managed a NIDA sponsored R01 evaluating a contingency management intervention with homeless, dually-diagnosed cocaine users. Most recently she worked as an Assistant Professor at the UAB School of Medicine.

Dr. Paul Schnur recently joined the Behavioral Sciences Research Branch, DNBR as a Health Scientist Administrator. Dr. Schnur is an experimental psychologist with interests in the neuropsychopharmacology of drug abuse. He has done both animal and human research and has published in the areas of classical conditioning, selective attention, memory, and behavioral pharmacology. Dr. Schnur brings his interests in cognitive psychology to NIDA and expects to assume some responsibility for new initiatives that integrate cognitive and behavioral science approaches to understanding drug abuse. Dr. Schnur earned his Ph.D. at Indiana University and completed NIDA supported post-doctoral training at Brown University's Center for Alcohol and Addiction Studies. He spent fourteen years at the University of Southern Colorado where he investigated biphasic effects of opiates on locomotor activity, conditioned tolerance/withdrawal and conditioned dopamine release in the n. accumbens. Prior to joining NIDA, Dr. Schnur served as Chairperson of the Department of Psychology at Indiana University South Bend.

Bryan Necciai, CAMCODA, formerly a temporary Office Automation clerk, converted to Secretary (OA) on June 18, 2000.

Moira O'Brien, DESPR, transferred from the Epidemiology Research Branch, DESPR, to the Community Research Branch, DESPR.

Mr. Arthur Hughes, Chief of the Epidemiology Research Branch, DESPR, left NIDA in June to join the Office of Applied Studies, SAMHSA, where he will work on the National Household Survey on Drug Abuse. Dr. James Colliver is serving as Acting Chief of ERB.

Gwen Jones left OSPC in August 2000 to accept a position as a program support assistant with the Food and Drug Administration (FDA); she will be working in the Office of the Commissioner, Office of International and Constituent Relations, Office of Women's Health.

Dr. Corina S. Pic left NIDA at the end of May 2000 after serving as an Intramural Research Training Associate (IRTA) Fellow in the Teen Tobacco Addiction Treatment Research Clinic. Dr. Pic went to the University of Maryland to begin her residency program in child psychiatry.


[Office of the Director][Report Index][Next Report Section]

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal